- Home
- MRNA
MRNA
Moderna Inc.
as 01-17-2025 4:00pm EST
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 16.0B | IPO Year: | 2018 |
| Target Price: | $76.35 | AVG Volume (30 days): | 10.5M |
| Analyst Decision: | Hold | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $31.94 - $170.47 | Next Earning Date: | 02-20-2025 |
| Revenue: | $5,081,000,000 | Revenue Growth: | -44.29% |
| Revenue Growth (this year): | -50.98% | Revenue Growth (next year): | -9.65% |
Stock Insider Trading Activity of Moderna Inc. (MRNA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Dec 6 '24 | Sell | $44.68 | 529 | $23,637.31 | 20,446 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Dec 2 '24 | Sell | $43.30 | 112 | $4,849.28 | 20,446 | |
| Hoge Stephen | MRNA | President | Dec 2 '24 | Sell | $43.30 | 314 | $13,595.29 | 1,443,904 | |
| Mock James M | MRNA | Chief Financial Officer | Nov 27 '24 | Sell | $42.79 | 1,420 | $60,760.52 | 11,066 | |
| Klinger Shannon Thyme | MRNA | Chief Legal Officer | Nov 27 '24 | Sell | $42.79 | 1,418 | $60,674.94 | 20,446 | |
| Hoge Stephen | MRNA | President | Nov 27 '24 | Sell | $42.79 | 291 | $12,451.63 | 1,443,904 | |
| Hoge Stephen | MRNA | President | Nov 8 '24 | Sell | $46.10 | 277 | $12,771.00 | 1,443,904 |
Latest Moderna Inc. News
MRNA Breaking Stock News: Dive into MRNA Ticker-Specific Updates for Smart Investing
The Wall Street Journal
20 hours ago
Moderna Gets $590 Million in Federal Funding for Bird Flu Vaccine
The Wall Street Journal
21 hours ago
The Score: Goldman Sachs, Nvidia, UnitedHealth and More Stocks That Defined the Week
Bloomberg
a day ago
Moderna Gets $590 Million from US to Study Bird Flu Vaccine
MT Newswires
a day ago
Moderna Gets $590 Million From US Government for Influenza Vaccine Program; Shares Rise After Hours
Barrons.com
a day ago
Moderna Is Getting $590 Million From the U.S. to Accelerate a Bird Flu Vaccine
ACCESS Newswire
a day ago
Moderna Announces Updates on Pandemic Influenza Program
Reuters
a day ago
US awards Moderna $590 million for bird flu vaccine development
Investor's Business Daily
a day ago
Here's How Donald Trump Could Shake Up Health Care — And Biotech Stocks
Compare MRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRNA Moderna Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.